APRAMEYA vs GKSL: Stock Comparison
GUJARAT KIDNEY N SUP SP L is the larger company by market capitalisation. APRAMEYA shows a lower P/E, a higher ROE and a higher ROCE, while GUJARAT KIDNEY N SUP SP L shows lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APRAMEYA leads 7; GKSL leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | APRAMEYA | GKSL |
|---|---|---|
| Live Price | — | ₹181.25 |
| Day Change | — | 1.93% |
| Volume | — | 2.73 L |
| 52-Week High | — | ₹183.05 |
| 52-Week Low | — | ₹98.36 |
| Distance from 52W High | — | -0.98% |
Valuation
| Metric | APRAMEYA | GKSL |
|---|---|---|
| Market Cap | ₹217 Cr | ₹1,443 Cr |
| P/E Ratio | 60.82x | 85.07x |
| P/B Ratio | 0x | 5.34x |
| EPS | ₹2.68 | ₹0.26 |
| Book Value | ₹36.54 | ₹32.31 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | APRAMEYA | GKSL |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0.7% | -73.04% |
| Qtr Profit Growth | 1.73% | -61.72% |
Profitability & Leverage
| Metric | APRAMEYA | GKSL |
|---|---|---|
| ROE | 7.37% | 4.02% |
| ROCE | 10.07% | 4.24% |
| Net Margin | 0% | 20.5% |
| Operating Margin | 19.83% | 34.16% |
| Debt to Equity | 0.1x | 0.06x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | APRAMEYA | GKSL |
|---|---|---|
| Promoter Holding | 74.05%▲ 0.52 pp | 71.45% |
| FII Holding | 0% | 4.88% |
| DII Holding | 0.7%▼ 0.07 pp | 0.56% |
| Public Holding | 25.24%▼ 0.46 pp | 23.1% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: APRAMEYA and GUJARAT KIDNEY N SUP SP L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.